200 related articles for article (PubMed ID: 16816797)
1. Implications of the CATIE trial on treatment: extrapyramidal symptoms.
Casey DE
CNS Spectr; 2006 Jul; 11(7 Suppl 7):25-31. PubMed ID: 16816797
[TBL] [Abstract][Full Text] [Related]
2. Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study.
Glazer WM; Conley RR; Citrome L
CNS Spectr; 2006 Sep; 11(9 Suppl 10):1-13; quiz 14. PubMed ID: 16946697
[TBL] [Abstract][Full Text] [Related]
3. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
Naber D; Lambert M
CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
[TBL] [Abstract][Full Text] [Related]
4. Interpreting the efficacy findings in the CATIE study: what clinicians should know.
Meltzer HY; Bobo WV
CNS Spectr; 2006 Jul; 11(7 Suppl 7):14-24. PubMed ID: 16816796
[TBL] [Abstract][Full Text] [Related]
5. Understanding the results of CATIE in the context of the field.
Glick ID
CNS Spectr; 2006 Jul; 11(7 Suppl 7):40-7. PubMed ID: 16816799
[TBL] [Abstract][Full Text] [Related]
6. Extrapyramidal side-effects of antipsychotics in a randomised trial.
Miller DD; Caroff SN; Davis SM; Rosenheck RA; McEvoy JP; Saltz BL; Riggio S; Chakos MH; Swartz MS; Keefe RS; Stroup TS; Lieberman JA;
Br J Psychiatry; 2008 Oct; 193(4):279-88. PubMed ID: 18827289
[TBL] [Abstract][Full Text] [Related]
7. Metabolic findings from the CATIE trial and their relation to tolerability.
Nasrallah HA
CNS Spectr; 2006 Jul; 11(7 Suppl 7):32-9. PubMed ID: 16816798
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability: how do newer generation "atypical" antipsychotics compare?
Tandon R
Psychiatr Q; 2002; 73(4):297-311. PubMed ID: 12418358
[TBL] [Abstract][Full Text] [Related]
9. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
[TBL] [Abstract][Full Text] [Related]
10. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
Novick D; Haro JM; Bertsch J; Haddad PM
J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
[TBL] [Abstract][Full Text] [Related]
11. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.
Barnes TR; McPhillips MA
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S49-57. PubMed ID: 9690971
[TBL] [Abstract][Full Text] [Related]
12. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.
Rosenheck RA; Davis VG; Davis SM; Stroup S; McEvoy J; Swartz M; Lieberman J
Schizophr Res; 2009 Aug; 113(1):12-8. PubMed ID: 19545976
[TBL] [Abstract][Full Text] [Related]
13. Effects of newer antipsychotics on extrapyramidal function.
Tarsy D; Baldessarini RJ; Tarazi FI
CNS Drugs; 2002; 16(1):23-45. PubMed ID: 11772117
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
15. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.
Leucht S; Wahlbeck K; Hamann J; Kissling W
Lancet; 2003 May; 361(9369):1581-9. PubMed ID: 12747876
[TBL] [Abstract][Full Text] [Related]
16. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
Gentile S
J Clin Psychopharmacol; 2007 Feb; 27(1):35-45. PubMed ID: 17224710
[TBL] [Abstract][Full Text] [Related]
17. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
Andrew HG
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
[TBL] [Abstract][Full Text] [Related]
18. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.
Pierre JM
Drug Saf; 2005; 28(3):191-208. PubMed ID: 15733025
[TBL] [Abstract][Full Text] [Related]
19. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
20. Choosing an atypical antipsychotic.
Sussman N
Int Clin Psychopharmacol; 2002 Aug; 17 Suppl 3():S29-33. PubMed ID: 12570069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
